Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.96
(
1.29%
)
Bitcoin
71,094.50
(
-0.21%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: flatlander_60048 post# 116341

Friday, 03/11/2011 11:24:52 PM

Friday, March 11, 2011 11:24:52 PM

Post# of 257257

…it seems like Roche is in a good position to know the positives and negatives of each drug, yet they chose to run expensive trials for the DME indication for Lucentis.

Roche is doing what any sensible company would do in this circumstance: get as many approved indications as possible for Lucentis and hope for the best in the head-to-head study with Avastin.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now